Form 4: Insider Buys & Conversions at Guided Therapeutics

John E. Imhoff, a Director and 10% owner of Guided Therapeutics Inc., reported several transactions including stock option exercises and convertible note conversions.

Summary

• John E. Imhoff, a Director and 10% owner of Guided Therapeutics Inc. (GTHP), has reported a series of transactions.
• On March 10, 2026, a stock option for 110,000 shares with an exercise price of $0.29 was exercised, with vesting scheduled to complete by March 10, 2029.
• On March 26, 2026, 10 shares of Series F preferred stock were converted into 40,000 shares of common stock, with the preferred stock having a stated value of $1,000 and a $0.25 conversion price.
• Also on March 26, 2026, 2,157 shares of common stock were acquired, and 10 shares of Preferred Series F stock were disposed of.
• On March 31, 2026, a convertible promissory note with a conversion price of $0.07 per share was converted, converting $11,019.18 (principal and accrued interest) into 157,417 shares of common stock. Following this conversion, $110,000 of principal remains outstanding under the note.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily details routine insider transactions and debt conversion rather than significant new strategic developments or financial performance indicators.

Positives

• Exercise of stock options indicates potential confidence in future stock value.
• Conversion of preferred stock and convertible notes into common stock can increase the company's equity base and reduce debt.
• The conversion of the convertible note at $0.07 per share suggests a favorable conversion price for the holder, potentially indicating a belief in the company's ability to reach a valuation supporting this price.

Negatives

• The conversion of a convertible promissory note implies outstanding debt that is being converted into equity, which can dilute existing shareholders.
• The remaining $110,000 principal on the convertible note, with potential conversion at a variable price upon default, represents an ongoing financial obligation and risk.

Risks

• The convertible promissory note has a remaining principal of $110,000, which is convertible into common stock at a variable price upon an event of default, posing a risk of further dilution and financial obligation.
• The vesting schedule for the stock options indicates that the full benefit of the option exercise is tied to continued service, implying a risk of forfeiture if service is not maintained.

Future Outlook

The filing details ongoing vesting for stock options until March 10, 2029, and a remaining convertible promissory note balance that could convert into common stock under certain conditions.

Industry Context

StockSavvy.ai notes that insider transactions, such as option exercises and debt-to-equity conversions, are common in early-stage or growth-oriented companies within the biotechnology and therapeutics sector. These actions can signal management's commitment and belief in the company's future prospects, but also highlight the ongoing need for capital and potential for dilution.

Related Party Transactions

• The transactions involve John E. Imhoff, who is a Director and 10% owner of Guided Therapeutics Inc., indicating these are related-party transactions.

Stakeholder Impact

• Shareholders may experience dilution if the remaining convertible note is converted into common stock.
• Employees who are also option holders may see increased equity participation as options vest and are exercised.
• Creditors of the convertible note are being converted into equity holders, changing their stakeholder status.

Next Steps

• Continued vesting of stock options through March 10, 2029.
• Potential conversion of the remaining $110,000 principal on the convertible promissory note under specific conditions.

Key Dates

Keywords

Form 4, Insider Trading, Guided Therapeutics, GTHP, Stock Options, Convertible Note, Preferred Stock, Beneficial Ownership, SEC Filing, Equity